Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.35 |
| ▸ | ALB | P02768 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13623603 | 1.00 | LMNA (0.46) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL19953828 | 1.00 | LMNA (0.46) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL13435075 | 1.00 | LMNA (0.46) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL26320640 | 0.83 | LMNA (0.63) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL20668731 | 0.83 | LMNA (0.63) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL9467302 | 0.83 | LMNA (0.63) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL13003005 | 0.83 | LMNA (0.63) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4384095 | 0.81 | LMNA (0.49) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL14473415 | 0.79 | SLC28A1 (0.44) | SLC29A1P2RY2P2RY12 | |
| SCHEMBL19953835 | 0.79 | SLC28A1 (0.44) | SLC29A1P2RY2P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453222-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9453222-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150232840-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | UNIVERSITY OF MASSACHUSETTS | 2015-08-20 | — | — | US | disclosed |
| EP-1791567-B1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20150191726-A1 | LIGAND-CONJUGATED MONOMERS | BANK OF AMERICA, N.A. | 2015-07-09 | — | — | US | disclosed |
| US-20150191726-A1 | LIGAND-CONJUGATED MONOMERS | BANK OF AMERICA, N.A. | 2015-07-09 | — | — | US | disclosed |
| US-8957223-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957223-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130261166-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | ALNYLAM PHARMACEUTICALS, INC. | 2013-10-03 | — | — | US | disclosed |
| US-20130261166-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | ALNYLAM PHARMACEUTICALS, INC. | 2013-10-03 | — | — | US | disclosed |
| US-20110251257-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | ALNYLAM PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-8017763-B2 | Chemically modified oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017763-B2 | Chemically modified oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20110027882-A1 | Methods and Compositions for Treating Neurological Disease | UNIVERSITY OF MASSACHUSETTS | 2011-02-03 | — | — | US | disclosed |
| US-20110027882-A1 | Methods and Compositions for Treating Neurological Disease | UNIVERSITY OF MASSACHUSETTS | 2011-02-03 | — | — | US | disclosed |
| US-20100267810-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | UNIVERSITY OF MASSACHUSETTS (US) | 2010-10-21 | — | — | US | disclosed |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7582744-B2 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070105803-A1 | Methods and compositions for treating neurological disease | MASSACHUSETTS, UNIVERSITY OF | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161591-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | LMNA 34/4885THRB 4505/4885MTOR 4374/4885 |
| US-20110251257-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | SMN1; SMN2, CLN6, INA | LMNA 34/4885THRB 4505/4885MTOR 4374/4885 |
| US-20150232840-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | SMN1; SMN2, CLN6, INA | LMNA 34/4885THRB 4505/4885MTOR 4374/4885 |
| US-20150191726-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | LMNA 3599/4885THRB 852/4885MTOR 4739/4885 |
| US-20100267810-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | SMN1; SMN2, CLN6, INA | LMNA 34/4885THRB 4505/4885MTOR 4374/4885 |
| US-20070105803-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | LMNA 34/4885THRB 4505/4885MTOR 4374/4885 |
| US-20130261166-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | SMN1; SMN2, CLN6, INA | LMNA 34/4885THRB 4505/4885MTOR 4374/4885 |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | LMNA 3599/4885THRB 852/4885MTOR 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.